Citius pharmaceuticals announces addition of city of hope to umn's phase 1 trial of lymphir in combination with car-t for the treatment of b-cell lymphoma

National cancer institute (nci)-designated research and treatment center city of hope, in duarte, ca, to participate in the university of minnesota (umn) masonic cancer center's ongoing phase 1 trial to determine the maximum tolerated dose of lymphir plus car-t therapy cranford, n.j. , april 11, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the university of minnesota masonic cancer center intends to expand their ongoing investigator-initiated phase 1 trial of lymphir™ (denileukin diftitox) in combination with fda-approved car-t products for the treatment of b-cell lymphomas.
CTXR Ratings Summary
CTXR Quant Ranking